



**Press Release**

Thursday, May 5, 2011



Strides Arcolab Limited,  
Strides House,  
Bannerghatta Road,  
Bangalore – 560076, India

BSE: 532531  
NSE: STAR

---

## **STRIDES ARCOLAB RECEIVES US FDA APPROVAL FOR MIDAZOLAM INJECTION MULTI-DOSE VIALS**

---


**May 5, 2011, Bangalore:** Strides Arcolab Limited (Strides) today announced that it has received US FDA approval for Midazolam injection USP, 1 mg/mL packaged in 10mg/10mL multiple-dose vials and 5mg/mL packaged in 25 mg/5mL and 50 mg/10mL multiple-dose vials.

Midazolam, a general anaesthetic, is offered as a sterile, non-pyrogenic parenteral dosage form for intravenous or intramuscular injections. Strides had earlier received US FDA approval for Midazolam Injection in strengths of 1 mg/mL (2, 5mL) and 5mg/mL (1, 2 mL) single dose vials. According to IMS September 2010 data, the total market for Midazolam in the USA approximated US\$ 51 million. With the combined approvals for single and multi-dose vials, Strides is now in a position to address over 95% of the sterile injectable market for Midazolam and will begin commercialization of Midazolam Injection in Q3.

Midazolam will be launched under the partnership between Strides and Sagent Pharmaceuticals wherein Strides is developing and supplying more than 25 injectable products for the USA market which will be marketed by Sagent.

### **About Agila Specialties**

Agila is the specialties unit of Strides Arcolab which was spun off as a separate division post the Company's restructuring in 2009. It is focused on key domains such as oncolytics, penems, pencillins, cephalosporins, ophthalmics, peptides and biosimilars and operates from 7 world class global manufacturing facilities, including one of the largest steriles capacity in India and amongst the largest lyophilization (freeze drying) capacities in the world. Agila's marketing network covers 70 countries and it has partnerships with some of the world's leading pharmaceutical companies for both developed and emerging markets.



## **About Strides Arcolab Limited**

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.

Additional information is available at the company's website at [www.stridesarco.com](http://www.stridesarco.com).

For further information, please contact:

<b><u>Strides</u></b>	<b><u>PR Consultancy</u></b>
Mr. V.S. Iyer, CEO - Agila +91 80 66580111	Corporate Voice   Weber Shandwick Mahesh Nair, +91 9880376648 <a href="mailto:maheshn@corvoshandwick.co.in">maheshn@corvoshandwick.co.in</a>
Mr. Ajay Singh – 080 66580813 Mr. Kannan N - +91 98450 54745 (Investors)	Hiba Kunil +91 98807 26372 <a href="mailto:hiba@corvoshandwick.co.in">hiba@corvoshandwick.co.in</a>
Melissa Arulappan (Media) +91 98450 22389	

